{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:59:14Z","timestamp":1792292354026,"version":"4.4.0"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The association between restless leg syndrome (RLS) and Parkinson disease (PD) remains unclear. Clarifying this association and the role of the dopaminergic pathway may improve understanding of the pathophysiology between these 2 diseases.<\/jats:p><\/jats:sec>Objectives<\/jats:title>To assess whether RLS is a risk factor for developing PD and whether the dopamine pathway is meaningfully associated with RLS and PD.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective cohort study used data from the Korean National Health Insurance Service Sample Cohort from 2002 to 2019. Statistical analyses were performed between September 2024 and March 2025. Patients with RLS and PD were identified based on codes from the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision<\/jats:italic> and matched to individuals without RLS. For the secondary analysis, the dopamine agonist (DA)\u2013treated group was operationally defined as patients with RLS who received DA during 2 or more distinct clinical visits, while those who did not meet this criterion were classified as the DA-nontreated group.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Diagnosis of RLS and treatment with DAs.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Development of PD. To compare the time to PD diagnosis across groups, a restricted mean survival time (RMST) analysis was conducted.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 9919 patients with RLS and 9919 matched controls were included. The mean (SD) age at enrollment was 50.1 (16.3) years in the control group (6225 women [62.8%]) and 50.3 (16.0) years in the RLS group (6225 women [62.8%]). The incidence of PD was 1.0% (99 of 9919) in the control group and 1.6% (158 of 9919) in the RLS group. At the prespecified time horizon of 15 years (\u03c4\u2009=\u200915), the RMST to PD diagnosis was 14.93 years in the control group and 14.88 years in the RLS group, resulting in a difference of \u22120.05 years (95% CI, \u20130.07 to \u20130.03 years). Compared with the control group, the DA-nontreated RLS group (n\u2009=\u20096842) showed a significantly shorter RMST to PD diagnosis (difference, \u20130.09 years [95% CI, \u20130.12 to \u20130.06 years]) and a higher incidence rate (143 of 6842 [2.1%]). The DA-treated RLS group (n\u2009=\u20093077) showed a significantly longer RMST to PD diagnosis (difference, 0.03 years [95% CI, 0.01-0.06 years]) and a lower incidence rate (15 of 3077 [0.5%]).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study, RLS was associated with an increased risk of developing PD. Furthermore, patients with RLS who were not treated with DAs tended to be at increased risk of developing PD, whereas those who were treated with DAs tended to be at decreased risk compared with the control group. These findings suggest that the pathophysiological connection between RLS and PD may involve mechanisms beyond the dopaminergic pathway.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.35759","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T15:00:30Z","timestamp":1759762830000},"page":"e2535759","source":"Crossref","is-referenced-by-count":4,"title":["Risk of Parkinson Disease Among Patients With Restless Leg Syndrome"],"prefix":"10.1001","volume":"8","author":[{"given":"Myeonghwan","family":"Bang","sequence":"first","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dougho","family":"Park","sequence":"additional","affiliation":[{"name":"Medical Research Institute, Pohang Stroke and Spine Hospital, Pohang, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Hun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurology, Korea University Ansan Hospital, Ansan, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoung Seop","family":"Kim","sequence":"additional","affiliation":[{"name":"Medical Research Institute, Pohang Stroke and Spine Hospital, Pohang, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"zoi251001r1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.sleep.2024.07.015","article-title":"Prevalence and clinical profile of patients with restless legs syndrome in Parkinson\u2019s disease: a meta-analysis.","volume":"121","author":"Maggi","year":"2024","journal-title":"Sleep Med"},{"issue":"2","key":"zoi251001r2","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1001\/archinte.164.2.196","article-title":"Sex and the risk of restless legs syndrome in the general population.","volume":"164","author":"Berger","year":"2004","journal-title":"Arch Intern Med"},{"key":"zoi251001r3","doi-asserted-by":"publisher","DOI":"10.13078\/jsm.230030","author":"Bugnicourt","year":"2024","journal-title":"J Sleep Med"},{"issue":"13","key":"zoi251001r4","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1002\/mds.23241","article-title":"Prevalence and clinical profile of restless legs syndrome in Parkinson\u2019s disease.","volume":"25","author":"Verbaan","year":"2010","journal-title":"Mov Disord"},{"issue":"1","key":"zoi251001r5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s13311-021-01019-4","article-title":"Restless legs syndrome: contemporary diagnosis and treatment.","volume":"18","author":"Gossard","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"2","key":"zoi251001r6","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsw065","article-title":"Association of restless legs syndrome with incident Parkinson\u2019s disease.","volume":"40","author":"Szatmari","year":"2017","journal-title":"Sleep"},{"issue":"2","key":"zoi251001r7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1001\/jamaneurol.2022.3902","article-title":"Widening the spectrum of risk factors, comorbidities, and prodromal features of Parkinson disease.","volume":"80","author":"Schrag","year":"2023","journal-title":"JAMA Neurol"},{"key":"zoi251001r8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3389\/fneur.2018.00551","article-title":"Restless legs syndrome and Parkinson disease: a causal relationship between the two disorders?","volume":"9","author":"Ferini-Strambi","year":"2018","journal-title":"Front Neurol"},{"issue":"2","key":"zoi251001r9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/mds.10307","article-title":"Restless legs syndrome in Parkinson\u2019s disease: a case-controlled study.","volume":"18","author":"Krishnan","year":"2003","journal-title":"Mov Disord"},{"issue":"6","key":"zoi251001r10","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1212\/WNL.61.6_suppl_3.S49","article-title":"Restless legs syndrome and PD: a review of the evidence for a possible association.","volume":"61","author":"Garcia-Borreguero","year":"2003","journal-title":"Neurology"},{"issue":"4","key":"zoi251001r11","doi-asserted-by":"publisher","first-page":"552","DOI":"10.4093\/dmj.2022.0193","article-title":"Current trends of big data research using the Korean National Health Information Database.","volume":"46","author":"Kim","year":"2022","journal-title":"Diabetes Metab J"},{"issue":"20","key":"zoi251001r12","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"zoi251001r13","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1428972","article-title":"Association between the length of stay in rehabilitation and mortality among the adults with Parkinson\u2019s disease: 2009-2019 Korean National Health Insurance Service Databases.","volume":"16","author":"Bae","year":"2024","journal-title":"Front Aging Neurosci"},{"key":"zoi251001r14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference.","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"issue":"3","key":"zoi251001r18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/archneur.59.3.421","article-title":"Exploring the relationship between Parkinson disease and restless legs syndrome.","volume":"59","author":"Ondo","year":"2002","journal-title":"Arch Neurol"},{"issue":"1","key":"zoi251001r19","doi-asserted-by":"publisher","first-page":"10547","DOI":"10.1038\/s41598-017-10593-7","article-title":"Restless legs syndrome in Parkinson disease: clinical characteristics, abnormal iron metabolism and altered neurotransmitters.","volume":"7","author":"Piao","year":"2017","journal-title":"Sci Rep"},{"key":"zoi251001r20","doi-asserted-by":"publisher","year":"2022","journal-title":"Bratisl Lek Listy","DOI":"10.4149\/BLL_2022_009"},{"issue":"15","key":"zoi251001r21","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1002\/mds.23256","article-title":"Restless legs syndrome and Parkinson\u2019s disease in men.","volume":"25","author":"Gao","year":"2010","journal-title":"Mov Disord"},{"issue":"1","key":"zoi251001r22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/2047-9158-1-6","article-title":"Linking restless legs syndrome with Parkinson\u2019s disease: clinical, imaging and genetic evidence.","volume":"1","author":"Peeraully","year":"2012","journal-title":"Transl Neurodegener"},{"issue":"2","key":"zoi251001r23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.5665\/sleep.3416","article-title":"Restless legs syndrome: an early clinical feature of Parkinson disease in men.","volume":"37","author":"Wong","year":"2014","journal-title":"Sleep"},{"issue":"5","key":"zoi251001r24","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1080\/13697130802359683","article-title":"Restless legs syndrome among women: prevalence, co-morbidity and possible relationship to menopause.","volume":"11","author":"Wesstr\u00f6m","year":"2008","journal-title":"Climacteric"},{"issue":"3","key":"zoi251001r25","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3233\/JPD-191627","article-title":"Sleep disturbance as potential risk and progression factor for Parkinson\u2019s disease.","volume":"9","author":"Bohnen","year":"2019","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"zoi251001r27","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/849472","article-title":"The interaction between obstructive sleep apnea and Parkinson\u2019s disease: possible mechanisms and implications for cognitive function.","volume":"2015","author":"Kaminska","year":"2015","journal-title":"Parkinsons Dis"},{"issue":"147","key":"zoi251001r28","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003748","article-title":"A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid \u00df.","volume":"4","author":"Iliff","year":"2012","journal-title":"Sci Transl Med"},{"issue":"6156","key":"zoi251001r29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.1241224","article-title":"Sleep drives metabolite clearance from the adult brain.","volume":"342","author":"Xie","year":"2013","journal-title":"Science"},{"key":"zoi251001r30","first-page":"309","article-title":"Brain iron and dopamine receptor function.","volume":"37","author":"Youdim","year":"1983","journal-title":"Adv Biochem Psychopharmacol"},{"issue":"12","key":"zoi251001r31","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1001\/archneur.59.12.1937","article-title":"A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.","volume":"59","author":"Group","year":"2002","journal-title":"Arch Neurol"},{"issue":"20","key":"zoi251001r32","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa.","volume":"342","author":"Rascol","year":"2000","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi251001r33","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov Disord"},{"issue":"S2","key":"zoi251001r34","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1002\/ana.21461","article-title":"Why have we failed to achieve neuroprotection in Parkinson\u2019s disease?","volume":"64","author":"Olanow","year":"2008","journal-title":"Ann Neurol"},{"issue":"6","key":"zoi251001r35","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2165\/00002512-200118060-00001","article-title":"Are dopamine receptor agonists neuroprotective in Parkinson\u2019s disease?","volume":"18","author":"Le","year":"2001","journal-title":"Drugs Aging"},{"issue":"4","key":"zoi251001r36","first-page":"S9","article-title":"Neuroprotection and dopamine agonists.","volume":"58","author":"Schapira","year":"2002","journal-title":"Neurology"},{"key":"zoi251001r37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1046\/j.1468-1331.9.s3.9.x","article-title":"Dopamine agonists and neuroprotection in Parkinson\u2019s disease.","volume":"9","author":"Schapira","year":"2002","journal-title":"Eur J Neurol"},{"issue":"20","key":"zoi251001r38","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1212\/WNL.0000000000012868","article-title":"Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: a report of the AAN guideline subcommittee.","volume":"97","author":"Pringsheim","year":"2021","journal-title":"Neurology"},{"key":"zoi251001r15","volume-title":"Statistical Methods for Meta-Analysis","author":"Hedges","year":"2014"},{"key":"zoi251001r16","author":"Cohen","year":"2013"},{"key":"zoi251001r17","first-page":"1","volume-title":"A Unified Approach to Measuring the Effect Size Between Two Groups Using SAS","author":"Yang","year":"2012"},{"key":"zoi251001r26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000325105","volume-title":"Obstructive Sleep Apnea in Adults","author":"Lurie","year":"2011"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2839651\/bang_2025_oi_251001_1759163692.87651.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T15:00:31Z","timestamp":1759762831000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2839651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.35759","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]}}}